Celularity (NASDAQ:CELU) Trading Down 3.4% – Here’s What Happened

Celularity, Inc. (NASDAQ:CELU) shares dropped 3.4% during mid-day trading on Wednesday . The company traded as low as $0.6281 and last traded at $0.6762. 392,390 shares were traded during trading, an increase of 167% from the average daily volume of 146,970 shares. The stock had previously closed at $0.6998.

Celularity Stock Down 3.4%

The company has a market cap of $19.58 million, a P/E ratio of -0.20 and a beta of 0.48. The business’s 50 day moving average is $0.92 and its 200 day moving average is $1.17.

Celularity (NASDAQ:CELU) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.85) earnings per share for the quarter. The company had revenue of $4.10 million during the quarter.

Institutional Investors Weigh In On Celularity

A number of large investors have recently modified their holdings of the business. XTX Topco Ltd grew its position in Celularity by 106.4% during the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after purchasing an additional 11,057 shares during the last quarter. Perennial Investment Advisors LLC purchased a new position in shares of Celularity during the 3rd quarter valued at about $28,000. Acadian Asset Management LLC acquired a new position in shares of Celularity in the first quarter worth about $34,000. Geode Capital Management LLC grew its position in shares of Celularity by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock valued at $178,000 after purchasing an additional 20,876 shares during the period. Finally, Bank of America Corp DE lifted its stake in shares of Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares in the last quarter. Hedge funds and other institutional investors own 19.02% of the company’s stock.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.